Skip to Content

Generic Nymalize Availability

Last updated on Sep 8, 2021.

Nymalize is a brand name of nimodipine, approved by the FDA in the following formulation(s):

NYMALIZE (nimodipine - solution;oral)

  • Manufacturer: ARBOR PHARMS LLC
    Approval date: May 10, 2013
    Strength(s): 3MG/ML (discontinued) [RLD]
  • Manufacturer: ARBOR PHARMS LLC
    Approval date: April 8, 2020
    Strength(s): 6MG/ML [RLD]

Has a generic version of Nymalize been approved?

No. There is currently no therapeutically equivalent version of Nymalize available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nymalize. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Non-aqueous liquid nimodipine compositions
    Patent 10,342,787
    Issued: July 9, 2019
    Assignee(s): ARBOR PHARMACEUTICALS, LLC

    Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein.

    Patent expiration dates:

    • April 16, 2038
      ✓ 
      Patent use: A METHOD FOR THE IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE (SAH) FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS
      ✓ 
      Drug product
  • Patent 10,576,070

    Patent expiration dates:

    • April 16, 2038
      ✓ 
      Patent use: A METHOD FOR THE IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE (SAH) FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS
      ✓ 
      Drug product
  • Dispenser for medicaments and method and apparatus for making same
    Patent 7,070,581
    Issued: July 4, 2006
    Inventor(s): Manera; David A. & Buehler; John D.
    Assignee(s): Comar, Inc.

    A dispenser assembly for liquid products comprising an elongated, generally cylindrical barrel of a predetermined internal cross-sectional diameter having a discharge opening at one end and open at its opposite end, an elongated, generally cylindrical hollow plunger having an outer diameter less than the barrel internal diameter and a circumferentially extending axially directed sealing lip adjacent the tip portion having an outer diameter greater than the internal diameter of the barrel in the relaxed state to thereby flex the lip inwardly against its bias and providing the sole sliding contact between the plunger and barrel when the plunger and barrel are actuated axially relative to one another.

    Patent expiration dates:

    • June 23, 2023
      ✓ 
      Drug product
  • Dispenser for medicaments and method and apparatus for making same
    Patent 8,517,997
    Issued: August 27, 2013
    Assignee(s): Comar, Inc.

    A dispenser assembly for liquid products is disclosed. Such an assembly may include an elongated barrel, and an elongated plunger having a flexible sealing lip disposed at an end thereof. The sealing lip may have an outer diameter in a relaxed state that is greater than an internal cross-sectional diameter of the barrel. When the plunger and barrel are actuated axially relative to one another, the sealing lip flexes inwardly and provides the sole contact between the plunger and the barrel.

    Patent expiration dates:

    • May 14, 2024
      ✓ 
      Drug product

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.